Atreca to Present at Upcoming Virtual Investor Conferences

Rhea-AI Summary

Atreca, a biotechnology company focusing on innovative therapeutics, announced presentations at two upcoming virtual investor conferences. The Cowen Oncology Innovation Summit will take place on May 21, 2021, at 10:40 a.m. EDT, followed by the Jefferies Healthcare Conference on June 2, 2021, at 3:30 p.m. EDT. Investors can access live audio webcasts via Atreca's website, with archived replays available for 90 days. Atreca is developing antibody-based immunotherapeutics, including the lead product candidate ATRC-101, currently in Phase 1b trials for multiple solid tumors.

SAN CARLOS, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming virtual investor conferences:

Cowen 2nd Annual Virtual Oncology Innovation Summit
Friday, May 21, 2021
Fireside chat time: 10:40 a.m. EDT

Jefferies Virtual Healthcare Conference
Wednesday, June 2, 2021
Fireside chat time: 3:30 p.m. EDT

A live audio webcast of each presentation can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. Archived replays will be available on the Company's website for 90 days following the live presentations.

About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

Forward-Looking Statements
Certain statements in this press release regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans and the timing thereof, constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, and regulatory submissions, the activity of ATRC-101 or potential future candidates once administered in human subjects, and the implementation of our strategic plans for our business, technologies, and current or potential future product candidates. More information on these risks and potential factors that could affect our business and financial results is included in our filings with the U.S. Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov, including in our most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and subsequent filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

Contacts

Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com

Investors:
Alex Gray, 650-779-9251, ext. 251
agray@atreca.com

Media:
Sheryl Seapy, 213-262-9390
sseapy@w2ogroup.com

Source: Atreca, Inc.

FAQ

What are the dates and times for Atreca's presentations at the investor conferences?

Atreca will present at the Cowen Oncology Innovation Summit on May 21, 2021, at 10:40 a.m. EDT and at the Jefferies Healthcare Conference on June 2, 2021, at 3:30 p.m. EDT.

How can I access Atreca's presentations during the investor conferences?

Live audio webcasts of Atreca's presentations can be accessed through the Events & Presentations section of their website.

What is the focus of Atreca's research and development?

Atreca focuses on developing novel antibody-based immunotherapeutics derived from its unique discovery platform that investigates the human immune response.

What is ATRC-101 and what stage is it in?

ATRC-101 is Atreca's lead product candidate currently undergoing evaluation in a Phase 1b study for multiple solid tumor cancers.

What should investors be aware of regarding forward-looking statements in Atreca's press release?

Investors should recognize that forward-looking statements may differ materially from actual results due to various risks and uncertainties, including those related to clinical trials and regulatory submissions.